A Prospective, Open-label, Randomized Phase III Study to Evaluate the Efficacy of ZOMETA (Zoledronic Acid) in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer.

Trial Profile

A Prospective, Open-label, Randomized Phase III Study to Evaluate the Efficacy of ZOMETA (Zoledronic Acid) in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Zoledronic acid (Primary) ; Cisplatin; Fluorouracil
  • Indications Cancer metastases; Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2012 Actual end date Sep 2009 added as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Feb 2009 Planned end date changed from 1 Dec 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top